Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate

Annals of Clinical Biochemistry

Volumn 33, Issue 2, 1996, Pages 159-161

  Collinson, P O ^a   Hjelm, C J ^a   Canepa Anson, R ^a  

^a MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Apolipoprotein A; Apolipoprotein B; CK; Liver dysfunction; Muscle damage

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN; ATENOLOL; BISOPROLOL; CIPROFIBRATE; ENALAPRIL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; WARFARIN;

ADULT; ARTICLE; ATHEROMA; CASE REPORT; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER DISEASE; LIVER FUNCTION; MALE; PATIENT MONITORING; PRIORITY JOURNAL; THROMBUS; XEROSTOMIA;

EID: 0029990153     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329603300213     Document Type: Article

References (7)

1. Scandinavian Simvastatin survival study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1383-9
2. Oliver M, Poole-Wilson P, Shepherd J, Tikkanen M. Lower patients' cholesterol now. BMJ 1995; 310: 1280-1
3. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronised fenofibrate and simvostatin in patients with primary type IIa or IIb hyperlipidaemia. Arch Intern Med 1994; 154: 441-9
4. Hahmann HW, Bunte T, Hellwig N, Hau U, Becker D, Dyckmans J, et al. Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am J Cardiol 1991; 67: 957-61
5. Chandler HA, Batchelor AJ. Ciprofibrate and lipid profile [Letter]. Lancet 1994; 344: 128-9
6. McLeod AJ, Warren RJ, Armitage M. Ciprofibrate and lipid profile [Letter]. Lancet 1994; 344: 955
7. Capps N. Lipid profiles on fibric acid derivatives [Letter]. Lancet 1994; 344: 684-5